Cited by 665Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Open access

Stein, Evan A., Mellis, Scott, Yancopoulos, George D., Stahl, Neil, Logan, Douglas, Smith, William B., Lisbon, Eleanor, Gutierrez, Maria, Webb, Cheryle, Wu, Richard, Du, Yunling, Kranz, Therese, Gasparino, Evelyn, Swergold, Gary D.·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1105803

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS: In healthy volunteers, we performed two randomized, single ascending-dose studies of REGN727 administered either intravenously (40 subjects) or subcutaneously (32 subjects), as compared with placebo. These studies were followed by a randomized, placebo-controlled, multiple-dose trial in adults with heterozygous familial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hypercholesterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >100 mg per deciliter [2.6 mmol per liter]) or a modified diet alone (10 subjects) (baseline LDL cholesterol, >130 mg per deciliter [3.4 mmol per liter]). REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43. The primary outcome for all studies was the occurrence of adverse events. The principal secondary outcome was the effect of REGN727 on the lipid profile. RESULTS: Among subjects receiving REGN727, there were no discontinuations because of adverse events. REGN727 significantly lowered LDL cholesterol levels in all the studies. In the multiple-dose study, REGN727 doses of 50, 100, and 150 mg reduced measured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per deciliter (2.00 mmol per liter), 61.3 mg per deciliter (1.59 mmol per liter), and 53.8 mg per deciliter (1.39 mmol per liter), for a difference in the change from baseline of -39.2, -53.7, and -61.0 percentage points, respectively, as compared with placebo (P<0.001 for all comparisons). CONCLUSIONS: In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01026597, NCT01074372, and NCT01161082.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1105803

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371

Show all 15 references

Research works printed but not linked: 1

Olsson AG, 2001, Clin Cardiol, 24, III

Sorted by citations

Items 401–500 of 665

PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs
Ho, V. Q. T., Tran, N. B., Nguyen, N. M. T., Arrighini, G. S., Downes, D., Dandamudi, M., Ferrara, V. Z., Ho, T. H. Q., Walia, H., Barbagelata, A., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003490 · Cited by 11
PCSK9 Inhibitors
Sible, A. M., Nawarskas, J. J., & Anderson, J. R. (2016) · Cardiology in Review · doi:10.1097/crd.0000000000000102 · Cited by 11
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design
Sgrignani, J., Fassi, E. M. A., Lammi, C., Roda, G., & Grazioso, G. (2020) · ChemMedChem · doi:10.1002/cmdc.202000431 · Cited by 11
Proprotein convertase subtilisin/kexin type 9 regulates the production of acute‐phase reactants from the liver
Sanz, D. J., Saralahti, A. K., Pekkarinen, M., Kesseli, J., Nykter, M., Rämet, M., Ojanen, M. J. T., & Pesu, M. (2021) · Liver International · doi:10.1111/liv.14993 · Cited by 11
Genetics of aortic valve disease
Ackah, R. L., Yasuhara, J., & Garg, V. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001028 · Cited by 12
The Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 13
Use and role of monoclonal antibodies and other biologics in preventive cardiology
Gencer, B., Laaksonen, R., Buhayer, A., & Mach, F. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14179 · Cited by 11
Running interference to lower cholesterol
Burnett, J. R., & Hooper, A. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61910-8 · Cited by 11
PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics
Rodríguez, F., & Knowles, J. W. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0487-8 · Cited by 13
The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology
Pitts, R., & Eckel, R. H. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.65 · Cited by 11
Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells
Loregger, A., Nelson, J. K., & Zelcer, N. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6875-6_5 · Cited by 12
Association of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study
Peloso, G. M., Lange, L. A., Varga, T. V., Nickerson, D. A., Smith, J. D., Griswold, M. E., Musani, S. K., Polfus, L. M., Mei, H., Gabriel, S., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001410 · Cited by 11
Alirocumab for the treatment of hypercholesterolaemia
Pepa, G. D., Bozzetto, L., Annuzzi, G., & Rivellese, A. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1318063 · Cited by 11
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations
Hopkins, P. N., Krempf, M., Bruckert, É., Donahue, S., Yang, F., Zhang, Y., & DiCioccio, A. T. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.007 · Cited by 11
Review of How Genetic Research on Segmental Progeroid Syndromes Has Documented Genomic Instability as a Hallmark of Aging But Let Us Now Pursue Antigeroid Syndromes !
Martin, G. M., Hisama, F. M., & Oshima, J. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa273 · Cited by 12
Instrumental variable and colocalization analyses identify endotrophin and HTRA1 as potential therapeutic targets for coronary artery disease
Lee, P. C., Jung, I., Thussu, S., Patel, V., Wagoner, R., Burks, K. H., Amrute, J., Elenbaas, J. S., Kang, C. J., Young, E. P., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110104 · Cited by 11
Genetic architecture of plasma metabolome in 254,825 individuals
Qiang, Y., Wang, Y., He, X., Deng, Y., Ge, Y., Wu, B., You, J., Feng, J., Cheng, W., & Yu, J. (2025) · Nature Communications · doi:10.1038/s41467-025-62126-w · Cited by 10
What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Stein, E. A. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000242 · Cited by 10
Self-citation
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 10
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 10
A functional SNP in FLT1 increases risk of coronary artery disease in a Japanese population
Konta, A., Ozaki, K., Sakata, Y., Takahashi, A., Morizono, T., Suna, S., Onouchi, Y., Tsunoda, T., Kubo, M., Komuro, I., et al. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2015.171 · Cited by 10
A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development
Udata, C., Garzone, P. D., Gumbiner, B., Joh, T., Hong, L., Liao, K., Williams, J. H., & Xu, M. J. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.867 · Cited by 10
The Use of Genomics to Drive Kidney Disease Drug Discovery and Development
Reilly, D. F., & Breyer, M. D. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11070919 · Cited by 10
A Journey through Genetic Architecture and Predisposition of Coronary Artery Disease
Roberts, R., & Chang, C. C. (2020) · Current Genomics · doi:10.2174/1389202921999200630145241 · Cited by 10
Antisense Oligonucleotides, microRNAs, and Antibodies
Dávalos, A., & Chroni, A. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_22 · Cited by 10
Recent developments in modulating atherogenic lipoproteins
White, C. R., Goldberg, D., & Anantharamaiah, G. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000216 · Cited by 10
PCSK9 Inhibition—A New Thrust in the Prevention of Heart Disease: Genetics Does It Again
Roberts, R. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.014 · Cited by 10
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
Luo, Q., Tang, Z., Wu, P., Chen, Z., Fang, Z., & Luo, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218968 · Cited by 9
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Arca, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.001 · Cited by 9
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Genetic loci associated with prevalent and incident myocardial infarction and coronary heart disease in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Hahn, J. M., Fu, Y., Brown, M. R., Bis, J. C., de Vries, P. S., Feitosa, M. F., Yanek, L. R., Weiß, S., Giulianini, F., Smith, A. V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230035 · Cited by 9
Lack of renoprotective effects by long-term PCSK9 and SGLT2 inhibition using alirocumab and empagliflozin in obese ZSF1 rats
Hummelgaard, S., Hvid, H., Birn, H., Glerup, S., Tom, N., Bilgin, M., Kirchhoff, J. E., & Weyer, K. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00065.2024 · Cited by 10
The Role of Genetic Risk Factors in Coronary Artery Disease
Dandona, S., & Roberts, R. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0479-2 · Cited by 9
Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
Toth, P. P. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.028 · Cited by 9
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
Teramoto, T., Kondo, A., Kiyosue, A., Harada‐Shiba, M., Ishigaki, Y., Tobita, K., Kawabata, Y., Ozaki, A., Baccara‐Dinet, M. T., & Sata, M. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0513-7 · Cited by 9
Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors
Xu, M., Liu, C. X., He, Y., Yang, X., & Zhao, X. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.04.32 · Cited by 9
Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
Duellman, S. J., Machleidt, T., Cali, J. J., & Vidugirienė, J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.d074658 · Cited by 9
Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II
Nicolas, X., Djebli, N., Rauch, C., Brunet, A., Hurbin, F., Martinez, J.-M., & Fabre, D. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0670-5 · Cited by 9
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Nicholls, S. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1103-2 · Cited by 10
Update of Clinical Trials of Anti-PCSK9 Antibodies
Wu, N., Li, S., & Li, J. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6582-9 · Cited by 8
Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis
Tang, M., Yang, S., Zou, J., Li, M., Sun, Y., Wang, M., Li, W., He, J., Chen, Y., & Tang, Z. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1336264 · Cited by 8
Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria
Hummelgaard, S., Kresse, J., Jensen, M. S., Glerup, S., & Weyer, K. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-025-03069-5 · Cited by 8
Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low‐Density Lipoprotein Cholesterol Lowering
Lose, J. M., Dorsch, M. P., & Bleske, B. E. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1222 · Cited by 8
New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention
Anderson, T. J. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.03.019 · Cited by 8
Resurgence of targets and compounds to treat dyslipidaemia
Kastelein, J. J. P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.132 · Cited by 8
The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels
de Keyser, C. E., Becker, M. L., Albert Hofman, D., Lous, J. J., Uitterlinden, A. G., Visser, L. E., & Stricker, B. H. C. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000120 · Cited by 8
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
Rana, K., Reid, J., Rosenwasser, J. N., Lewis, T., Sheikh‐Ali, M., Choksi, R. R., & Goldfaden, R. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s167375 · Cited by 8
Glucagon-like peptide-1 receptor and sarcoglycan delta genetic variants can affect cardiovascular risk in chronic kidney disease patients under hemodialysis
Terranegra, A., Arcidiacono, T., Macrina, L., Brasacchio, C., Pivari, F., Mingione, A., Tomei, S., Mezzavilla, M., Silcock, L., Cozzolino, M. G., et al. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz182 · Cited by 8
Powerful Tukey's One Degree-of-Freedom Test for Detecting Gene-Gene and Gene-Environment Interactions
Wang, Y., Li, D., & Wei, P. (2015) · Cancer Informatics · doi:10.4137/cin.s17305 · Cited by 8
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W., & Walford, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00041-x · Cited by 10
T ranslational A dvances in the F ield of P ulmonary H ypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension
Gladwin, M. T. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1637ed · Cited by 8
How will new medications affect the lipoprotein apheresis situation in Germany?
Parhofer, K. G. (2013) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.10.022 · Cited by 7
The Causal Relationship between PCSK9 Inhibitors and Osteoporosis Based on Drug-Targeted Mendelian Combined Mediation Analysis
Zhang, N., Ji, C., Liu, L., Ye, E., & Yuan, C. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01228-x · Cited by 7
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
Duprez, D. A., Handelsman, Y., & Koren, M. J. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s261719 · Cited by 8
Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
Zhao, Z., Hu, X. Y., Zhang, Y., & Liu, D. (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31197 · Cited by 7
Unraveling New Therapeutic Targets of Coronary Artery Disease by Genetic Approaches
Lee, S. E., & Kim, H.-S. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0985 · Cited by 7
Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy
Milionis, H. J., Liamis, G. L., & Elisaf, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.984682 · Cited by 7
Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates
Gusarova, V., HOWARD, V. G., Okamoto, H., Koehler-Stec, E. M., Papadopoulos, N. J., Murphy, A. J., Yancopoulos, G. D., Stahl, N., & Sleeman, M. W. (2012) · Clinical Lipidology · doi:10.2217/clp.12.70 · Cited by 7
Self-citation
Evolocumab in Hyperlipidemia
Blom, D. J., Wasserman, S. M., & Stein, E. A. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1408237 · Cited by 7
Self-citation
PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Stein, E. A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6690-1 · Cited by 7
Self-citation
Using multiple 'omics strategies for novel therapies in sepsis
Russell, J. A., Spronk, P. E., & Walley, K. R. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5122-z · Cited by 7
A Breakthrough in Genetics and its Relevance to Prevention of Coronary Artery Disease in LMIC
Roberts, R. (2017) · Global Heart · doi:10.1016/j.gheart.2017.04.001 · Cited by 6
Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study
Shu, Y., Deng, Z., Deng, Y., Zhou, J., Wang, J., Duan, Z., Jiang, T., Zhao, X., Shi, Z., & Qiu, C. (2023) · BMC Emergency Medicine · doi:10.1186/s12873-023-00896-6 · Cited by 6
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Inhibition of PCSK9 in familial hypercholesterolaemia
Sijbrands, E. J. G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60814-9 · Cited by 6
Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice
Sabatine, M. S., Underberg, J. A., Koren, M. J., & Baum, S. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1208895 · Cited by 6
The biological relevance of PCSK9: when less is better…
Mbikay, M., & Chrétien, M. (2022) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0540 · Cited by 6
Novel Therapies for Treating Familial Hypercholesterolemia
Bandeali, S. J., Daye, J., & Virani, S. S. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0382-0 · Cited by 7
Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega–3 polyunsaturated fatty acid ethyl esters
Halcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
Eligibility for PCSK-9 inhibitors treatment in acute coronary syndrome, chronic coronary artery disease and outpatient dyslipidemic patients
Vlachopoulos, C. V., Dima, I., Soulis, D., Terentes-Printzios, D. G., Skoumas, I., Aznaouridis, K. A., Solomou, E. G., Richter, D. J., & Tousoulis, D. M. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.024 · Cited by 6
Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia
Devito, F., Zito, A., Ricci, G., Carbonara, R., Dentamaro, I., Cortese, F., Carbonara, S., & Ciccone, M. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.021 · Cited by 6
Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors
Eisen, A., & Giugliano, R. P. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000332 · Cited by 6
Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors
Sahebkar, A. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.139-c1 · Cited by 6
Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
Qureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 5
Low-density lipoprotein cholesterol lowering therapies
Gadi, R., & Figueredo, V. M. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000193 · Cited by 5
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
Assessing the functional consequence of loss of function variants using electronic medical record and large-scale genomics consortium efforts
Abou‐Sleiman, P. M., Bradfield, J. P., Mentch, F. D., Almoguera, B., Connolly, J. J., & Hakonarson, H. H. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00105 · Cited by 6
Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics–Pharmacodynamics and Systems Pharmacology
Peng, J., Huang, J., Tan, H., Kuang, Y., Yang, G., & Huang, Z. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00256 · Cited by 5
Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis
Nasso, G., Larosa, C., Bartolomucci, F., Brigiani, M. S., Contegiacomo, G., Demola, M. A., Vignaroli, W., Tripoli, A., Girasoli, C., Lisco, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030907 · Cited by 5
The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy
Wańczura, P. M., Aebisher, D., Iwański, M. A., Myśliwiec, A., Dynarowicz, K., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12050961 · Cited by 5
The role of protective genetic variants in modulating epigenetic aging
Bejaoui, Y., Srour, L., Qannan, A., Oshima, J., Saad, C., Horvath, S., Mbarek, H., & Hajj, N. E. (2025) · GeroScience · doi:10.1007/s11357-025-01548-2 · Cited by 5
Recent Developments in the Treatment of Familial Hypercholesterolemia: A Review of Several New Drug Classes
Wilkinson, M. J., & Davidson, M. H. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0272-3 · Cited by 5
The physiological paradox: reframing the polypill as a vaccine for cardiovascular disease
Holmes, M. V., & Bhala, N. B. (2013) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2013-202690 · Cited by 5
JCL roundtable: PCSK9 inhibitors in clinical practice
Brown, W. V., Moriarty, P. M., & McKenney, J. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.004 · Cited by 5
Case 16-2013
Bender, S. L., Sherry, N., & Masia, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1208145 · Cited by 5
PCSK9 inhibitors
Denegri, A., Petrova-Slater, I., Pasotti, E., Rossi, M. G., Pedrazzini, G., Moccetti, T., & Moccetti, M. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000360 · Cited by 5
Una historia resumida. La inhibición de la PCSK9 y su desarrollo clínico
Lopez-Sendon, J. L., Castro, A., & Dalmau, R. (2017) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(19)30011-1 · Cited by 7
Recent updates in dyslipidemia management: perspectives in stroke-specific situation
Seo, W., Hosseini, M. B., Bang, O. Y., & Liebeskind, D. S. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00009 · Cited by 5
Cardiovascular pharmacology: a look back and a glimpse into the future
Braunwald, E. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu002 · Cited by 5
Molecular Genetics of Coronary Artery Disease
Ozaki, K. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0027329 · Cited by 5
Inherited risk of coronary artery disease: redefining care with imaging and genetics
Lan, N. S. R., Dwivedi, G., Hillis, G. S., Chew, D. P., Yeap, B. B., Figtree, G. A., Khera, A. V., Watts, G. F., & Ihdayhid, A. R. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01254-2 · Cited by 4
Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial
Na, H. R., Kwon, O., Kang, J. K., Kim, Y. H., & Lim, J. Y. (2022) · Trials · doi:10.1186/s13063-022-06398-3 · Cited by 4
The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial
Lin, L., Luo, S., Cai, K., Huang, H., Liang, H., Zhong, L., & Xu, Y. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2408222 · Cited by 4
Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol
Liu, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.150 · Cited by 4
PCSK9, a novel target for lowering LDL cholesterol: promise and progress
Tavori, H., Fazio, S., & Linton, M. F. (2012) · Clinical Lipidology · doi:10.2217/clp.12.72 · Cited by 4
Highlighting the future potential of PCSK9-targeted therapeutics
Dowdall, M. J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.78 · Cited by 4
The State of Whole-Genome Sequencing
Dervan, A., & Shendure, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800681-8.00003-7 · Cited by 4
Heart Failure Prevention
Taimeh, Z. A., Duprez, D. A., & Garry, D. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-44577-9_18 · Cited by 4
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Nicholls, S. J. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.3.2 · Cited by 4

Authors: Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., & Swergold, G. D.
Affiliations: Regeneron (United States) (US)
Medpace (United States) (US)
University of Tennessee Medical Center (US)
IQVIA (United States) (US)
ORCID: Stein, Evan A.
Mellis, Scott
Stahl, Neil
Lisbon, Eleanor
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-03-22
Volume: 366
Issue: 12
Pages: 1108-1118
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1105803
OpenAlex: W1989730880
Semantic Scholar: 04c1ea8c55c4bae0da3106e47141bac81e1bb585
Cited by: 664
References: 15
Citations by year: 2026: 12 · 2025: 11 · 2024: 29 · 2023: 22 · 2022: 19 · 2021: 20 · 2020: 38 · 2019: 29 · 2018: 46 · 2017: 58 · 2016: 62 · 2015: 86 · 2014: 83 · 2013: 92 · 2012: 57
FWCI: 103.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Sanofi
Regeneron Pharmaceuticals
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: PCSK9, monoclonal antibodies, LDL cholesterol, LDL receptor degradation, hypercholesterolemia, familial hypercholesterolemia, atorvastatin, lipid profile, adverse events, dose escalation, cholesterol absorption inhibition
MeSH terms: Atorvastatin, Proprotein Convertase 9, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Hyperlipoproteinemia Type II, Injections, Intravenous, Injections, Subcutaneous, Lipoproteins, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Receptors, LDL, Serine Endopeptidases, Least-Squares Analysis, Proprotein Convertases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks